GlassScriptPhysician profile
William A Mccrory
NPI 1023070323
$5,323.99
in general payments reported to CMS, 2019-2025
27 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $671 · 2021: $714 · 2022: $920 · 2023: $646 · 2024: $653 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.47 |
| Education | $167.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,730.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $836.24 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $534.36 | 2021-2024 | Dupixent |
| Insmed, INC. | $499.68 | 2020-2024 | Arikayce |
| Genentech USA, INC. | $282.43 | 2019-2020 | |
| Amgen INC. | $252.48 | 2024-2025 | Tezspire |
| Gilead Sciences, INC. | $178.74 | 2021-2023 | |
| Philips North America LLC | $149.79 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $109.98 | 2024-2025 | |
| Inspire Medical Systems, INC. | $80.07 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $73.94 | 2020-2023 | Glassia |
| Cumberland Pharmaceuticals, INC. | $69.54 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.69 | 2019-2024 | Ofev |
| Genzyme Corporation | $66.29 | 2022-2025 | |
| Electromed, INC. | $66.24 | 2019-2025 | Smartvest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $66.16 | 2020-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $49.56 | 2019-2020 | |
| United Therapeutics Corporation | $41.10 | 2021-2023 | Tyvaso |
| Pulmonx Corporation | $38.32 | 2019-2021 | |
| Csl Behring | $24.46 | 2020 | |
| 3b Medical, INC. | $18.18 | 2025 | Luna |
| Novartis Pharmaceuticals Corporation | $18.02 | 2019 | |
| Verona Pharma, INC. | $17.30 | 2025 | Ohtuvayre |
| Resmed Corp | $14.26 | 2025 | |
| Lilly USA, LLC | $13.49 | 2025 | Zepbound |
| Mayne Pharma Commercial LLC | $12.58 | 2019 | |
| La Jolla Pharmaceutical Company | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mccrory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.